tetano
Editor, Senior Moderator
Clin Appl Thromb Hemost
. 2022 Jan-Dec;28:10760296221120421.
doi: 10.1177/10760296221120421.
Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States
W Frank Peacock[SUP] 1 [/SUP], James M Crawford[SUP] 2 3 [/SUP], Yen-Wen Cindy Chen[SUP] 4 [/SUP], Veronica Ashton[SUP] 4 [/SUP], Alicia K Campbell[SUP] 4 [/SUP], Dejan Milentijevic[SUP] 4 [/SUP], Alex C Spyropoulos[SUP] 2 3 5 [/SUP]
Affiliations
Abstract
Limited data are available on thromboembolic events (TEEs) and mortality in outpatients with coronavirus disease 2019 (COVID-19). This retrospective, observational cohort study identified non-hospitalized COVID-19 outpatients (01/21/2020-01/07/2021) using de-identified Optum[SUP]®[/SUP] COVID-19 Electronic Health Records data. Patient characteristics, occurrence of TEEs, all-cause mortality, and anticoagulant or thrombolytic medication use were evaluated. Of 1,246,067 patients with COVID-19 diagnosis, 141 471 met entry criteria. Mean (standard deviation [SD]) age was 46.1 (17.2) years, 56.8% were female, 72.9% Caucasian, 11.2% African American, and 11.1% Hispanic. Comorbidity burden was low (mean [SD] Quan-Charlson comorbidity index score of 0.43 [1.10]); however, of those with body mass index data, half were obese. During the follow-up period, a TEE occurred in 1.4%, with the proportion of patients with ischemic stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism being similar (approximately 0.4% each). All-cause mortality was 0.7%. Medications included corticosteroids (13.7%), anticoagulants (4.9%), and antiplatelets (2.9%). Overall, in this large cohort analysis, certain demographic and clinical characteristics of patients who experienced TEEs were identified and may help guide management decisions and future clinical trials for COVID-19 outpatients.
Keywords: COVID-19; anticoagulation; risk factors; thromboembolism; thrombosis.
. 2022 Jan-Dec;28:10760296221120421.
doi: 10.1177/10760296221120421.
Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States
W Frank Peacock[SUP] 1 [/SUP], James M Crawford[SUP] 2 3 [/SUP], Yen-Wen Cindy Chen[SUP] 4 [/SUP], Veronica Ashton[SUP] 4 [/SUP], Alicia K Campbell[SUP] 4 [/SUP], Dejan Milentijevic[SUP] 4 [/SUP], Alex C Spyropoulos[SUP] 2 3 5 [/SUP]
Affiliations
- PMID: 35996822
- DOI: 10.1177/10760296221120421
Abstract
Limited data are available on thromboembolic events (TEEs) and mortality in outpatients with coronavirus disease 2019 (COVID-19). This retrospective, observational cohort study identified non-hospitalized COVID-19 outpatients (01/21/2020-01/07/2021) using de-identified Optum[SUP]®[/SUP] COVID-19 Electronic Health Records data. Patient characteristics, occurrence of TEEs, all-cause mortality, and anticoagulant or thrombolytic medication use were evaluated. Of 1,246,067 patients with COVID-19 diagnosis, 141 471 met entry criteria. Mean (standard deviation [SD]) age was 46.1 (17.2) years, 56.8% were female, 72.9% Caucasian, 11.2% African American, and 11.1% Hispanic. Comorbidity burden was low (mean [SD] Quan-Charlson comorbidity index score of 0.43 [1.10]); however, of those with body mass index data, half were obese. During the follow-up period, a TEE occurred in 1.4%, with the proportion of patients with ischemic stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism being similar (approximately 0.4% each). All-cause mortality was 0.7%. Medications included corticosteroids (13.7%), anticoagulants (4.9%), and antiplatelets (2.9%). Overall, in this large cohort analysis, certain demographic and clinical characteristics of patients who experienced TEEs were identified and may help guide management decisions and future clinical trials for COVID-19 outpatients.
Keywords: COVID-19; anticoagulation; risk factors; thromboembolism; thrombosis.